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Introduction
Hereditary spastic paraplegia (HSP) encompasses a highly heterogeneous group of disorders characterized clinically by features of upper motor neuron lesion including spasticity, weakness, increased tendon reflexes and upward going plantar reflexes; the term complex HSP is used when these features are associated with other neurological or non-neurological features (Finsterer et al., 2012; Fink, 2013; Lo Giudice et al., 2014; Noreau et al., 2014) . Many genes have been implicated in the pathology of HSP, encoding molecules with diverse functional roles (Lo Giudice et al., 2014; Noreau et al., 2014) , including a number of genes involved in lipid metabolism (CYP7B1, CYP2U1, DDHD1, DDHD2, BSCL2, ERLIN2, FA2H and PNPLA6/NTE) (Windpassinger et al., 2004; Rainier et al., 2008; Goizet et al., 2009; Alazami et al., 2011; Schuurs-Hoeijmakers et al., 2012; Tesson et al., 2012; Cao et al., 2013; Gonzalez et al., 2013) . Here, we investigated four individuals from a single consanguineous Omani family aged between 19 months and 15 years (Fig. 1A ) that presented with an unusual neurodegenerative condition best categorized clinically as a complex form of HSP with brain white matter involvement.
Materials and methods
Standard protocol approvals, registrations, and patient consents Informed consent was obtained from participating individuals or their legal guardians and research was performed according to institutional, national and international human subject research guidelines.
Genetic studies
Genomic DNA samples were extracted from peripheral blood following standard protocols. Genome-wide genotyping was carried out using Illumina HumanCytoSNP-12 v2.1SNP arrays. Data output was visualized in Illumina's GenomeStudio software. Multipoint linkage analysis was performed assuming a recessive mode of inheritance, full penetrance, and a disease allele frequency of 0.0001 using SimWalk2 (Sobel and Lange, 1996) .
Whole exome sequencing was performed by Otogenetics Corp. using the SureSelect Human All Exon V4 (Agilent Technologies) exome enrichment kit on an Illumina HiSeq2000. Reads were analysed on the DNAnexus platform for exome coverage, SNP/ InDel variant calling and quality filtering. The exome sequencing produced 21 907 356 mapped 100 bp paired-end reads, matching 95.92% of targeted sequences adequately covered for variant calling (410Â coverage; mean depth, 38.4Â ).
The identified putative mutations were validated by PCR amplification followed by di-deoxy sequence analysis (Applied Biosystems 3130 DNA Sequencer, Life Technologies). Primer design to amplify the coding exon 5 of the SELENOI/EPT1 gene was done using Primer3 online tool (Rozen and Skaletsky, 2000) . Primer sequence specificity was verified by using the UCSC In-Silico PCR tool and their sequences were screened to exclude common single nucleotide polymorphisms.
Expression of human EPT1 in yeast
Open reading frames encoding full-length wild-type human SELENOI/EPT1, and the c.335G 4 C (p.Arg112Pro) mutated allele identified in patients, were subcloned into the Saccharomyces cerevisiae expression vector p416-GPD with a 3' extension encoding Myc and DDK tags allowing for constitutive expression from the GPD1 promoter. The TGA codon encoding selenocysteine at amino acid 387 of EPT1 was changed to a cysteine encoding TGT codon by site-directed mutagenesis. Plasmids bearing the wild-type and the mutant allele of human SELENOI/EPT1 were transformed into the yeast strain HJ091 (ept1-1 cpt1::LEU2), which is devoid of endogenous ethanolaminephosphotransferase activity (Henneberry and McMaster, 1999; Henneberry et al., 2000) . Yeast cells containing the SELENOI/ EPT1 expression plasmids were grown to mid-log phase and whole cell extracts were prepared and fractionated into soluble and membranous fractions by centrifugation at 100 000 g for 1 h. Western blots using anti-DDK antibodies were performed to determine EPT1 protein expression, with Pgk1 (cytosolic fraction) and Dpm1 (membrane fraction) used as loading controls.
In vivo phospholipid radiolabelling
Yeast cells were grown to mid-log phase in 10 ml of synthetic defined medium. Cells were pelleted, washed with synthetic define medium without ammonium sulphate and resuspended in 4 ml of the same medium containing 14 C-ethanolamine (3 mM, 244 000 dpm/nmol). Cells were cultivated for 1 h at 30 C. At the end of the radiolabelling period cells were harvested, washed with ice-cold water and processed for lipid extraction. Briefly, cells were resuspended in 1 ml of CHCl 3 / CH 3 OH (1:1) and disrupted by bead beating for 1 min at 4 C. The beads were washed with 1 ml of CHCl 3 /CH 3 OH (2:1), and 1.5 ml of H 2 O and 1 ml of CHCl 3 /CH 3 OH (5:1) were added to the combined supernatant to facilitate phase separation. Phospholipids in the organic phase were analysed by thin layer chromatography on Whatman Silica Gel 60A plates using the solvent system CHCl 3 /CH 3 OH/H 2 O/CH 3 COOH (70/ 30/2/2). Plates were scanned with a BioScan radiolabel imaging scanner, and the bands corresponding to phosphatidylethanolamine (PE) and phosphatidylcholine (PC) were scraped into vials for liquid scintillation counting (Henneberry and McMaster, 1999) . Lipid phosphorous was determined as described by Ames and Dubin (1960) . Data represent the mean AE standard error of three independent determinations.
Lipidomic analysis of blood samples
Whole blood from the four affected individuals and their parents (carriers) as well as from five controls was taken for blood phospholipid measurements. Lipid extraction was performed using a modified Bligh and Dyer extraction (Bligh and Dyer, 1959) . Briefly, 10 ml of blood was transferred into weighed 2.0 ml Eppendorf tubes. One hundred and eighty microlitres of chilled chloroform/methanol (1:2; v/v) containing internal standards was added. The incubate was vortexed to mix (15 s) with agitation on a thermo mixer (400 rpm) at 4 C in the dark for 1 h (single phase). Sixty microliters of chilled chloroform and 50 ml chilled Milli-Q Õ water was added and the sample was then vortexed to mix (15 s) and centrifuged at 10 000 rpm for 7 min to separate the phases. The lower organic phase was transferred into clean 2.0 ml microfuge tube (first organic extract). The first organic extract was centrifuged in a vacuum concentrator (SpeedVac) for 10 min. The remaining aqueous phase was re-extracted using 100 ml of chilled chloroform. It was then vortexed to mix (15 s), and centrifuged at 10 000 rpm for 7 min to separate the phases. Lower organic phase was transferred into the first organic extract. The pooled organic extract was dried in a vacuum concentrator (SpeedVac). The lipid extract was resuspended with 200 ml of chilled chloroform/methanol (1:2; v/v). It was then stored at À80 C until mass spectrometry analysis.
For LC/MS analysis, 20 ml aliquots of samples were added into glass vials with glass inserts. A QC sample was generated by pooling 10 ml of each sample together. The sample injection volume was 2 ml. Lipids were separated using gradient elution. Mobile phase A: 40% acetonitrile / 60% 10 mM ammonium formate in H 2 O; mobile phase B: 90% isopropanol / 10% 10 mM ammonium formate in H 2 O. Column: Agilent Zorbax Eclipse plus C18, length: 50 mm, internal diameter: 4.6 mm, particle size: 1.8 mm. Column temperature: 40 C. The flow rate was 0.4 ml/min and the gradient as follows: initial: 20% B, increase to 60% B in 2 min, increase to 100% B in 5 min, stay at 100% B for 2 min, decrease to 20% B in 0.01 mins, keep at 20% B until end of run (10.8 min).
Samples were randomized using Excel for injection into LC/ MS instrument and the QC sample was injected after every six samples. To avoid carry over, every QC injection was followed by a blank injection. This injection sequence was repeated three times (technical triplicates). Quantification data were extracted using Agilent MassHunter Quantitative Analysis (QQQ) software. The data were manually curated to ensure that the software integrated the correct peaks. Area under the curve (AUC) of lipids were normalized to AUC of internal standards.
Results

Clinical studies
Four children from an extended Omani pedigree aged between 19 months and 15 years and affected by a complex neurodegenerative phenotype. The affected individuals presented in infancy/early childhood with delayed gross motor development, progressive spastic paraperesis and gradual decline in motor function. The oldest affected individual has evidence of upper limb involvement. All affected individuals also manifest an apparently non-progressive mild intellectual impairment. A delay in language acquisition was universal, with dysarthria becoming more noticeable with advancing age. Neuroimaging in all four individuals revealed increased T 2 intensity signal in the periventricular white matter. The oldest affected child had neurophysiological evidence of a demyelinating peripheral neuropathy; however, upper motor neuron signs predominate over any clinical manifestations of this. Associated variable features included microcephaly, seizure activity and bifid uvula with or without cleft palate. Generalized retinal pigment epithelium level pigmentary disturbance was seen in two of the children, full-field electroretinography, performed in one of these children was consistent with cone-rod dysfunction. Therefore, a clinical diagnosis of complicated hereditary spastic paraplegia had been assigned to these families, although there are additional features present in some individuals that provide evidence of a broader phenotype associated with disturbance of the Kennedy pathway phospholipid cascade (Table 1) .
Genetic studies
To determine the genomic location of the gene responsible, we undertook genome-wide single nucleotide polymorphism (SNP) genotyping of DNA extracted from blood from family members assuming, autosomal recessive inheritance and that a founder mutation was responsible. This identified a single notable autozygous region of 21.75 Mb on chromosome 2 p, delimited by markers rs4669407 and rs207423 ( Fig. 1A and Supplementary Fig. 1 ), likely to correspond to the disease locus. To identify the causative mutation, we performed whole exome sequencing on an affected family member (Patient V:1). After filtering the identified variants for call quality, potential pathogenicity, population frequency (0.01%) and localization within the candidate interval a single sequence variant located within the disease locus was identified, in ethanolaminephosphotransferase 1 (SELENOI/EPT1; NM_033505.2; chr2:26,373,391G 4 C; c.335G 4 C; p.Arg112Pro; Fig. 1B) . The variant affects a stringently conserved arginine residue (p.Arg112Pro; Fig. 1C ), which is predicted to be damaging by in silico analysis (PolyPhen-2 (Majava et al., 2007) and PROVEAN (Choi et al., 2012) , and was found to co-segregate in the family as appropriate for an autosomal recessive condition ( Fig. 1A) , is not present in online genomic variant databases (1000 Genomes, Exome Variant Server, and Exome Aggregation Consortium (ExAC) and was also absent in 100 regional Omani control subjects.
Expression of human EPT1 in yeast
To determine the likely pathogenicity of the variant, we next investigated the effect of the p.Arg112Pro mutation on EPT1 activity. SELENOI/EPT1 encodes a CDP-ethanolamine specific enzyme that catalyses the final step in the synthesis of PE via the Kennedy pathway ( Fig. 2A) (Horibata and Hirabayashi, 2007) . EPT1 belongs to a superfamily of integral membrane phospholipid synthesising enzymes that catalyse displacement of CMP from a CDP-alcohol by a second alcohol with formation of a phosphodiester bond to synthesize a phospholipid. This family of enzymes contains a highly conserved catalytic motif, the CDP-alcohol phosphotransferase motif DG(X 2 )AR(X 8 )G(X 3 )D(X 3 )D (Williams and McMaster, 1998) , which for EPT1 is found between amino acid residues 107-129 ( 107 DGKQAR 112 RTNSSTPLGELFD HGLD 129 ). As the sequence alteration described here affects the highly conserved arginine residue (p.Arg112Pro) within this CDP-alcohol phosphotransferase motif, we examined whether the alteration affects EPT1 catalytic activity.
In order to determine this, human EPT1 and mutant EPT1 Arg112Pro were expressed from a constitutive promoter in a S. cerevisiae strain devoid of endogenous ethanolaminephosphotransferase activity, and their capacity to synthesize PE was determined by metabolic labelling studies. Western blots demonstrated that both human SELENOI/EPT1 alleles were expressed in yeast at comparable levels indicating that protein stability was not affected, were associated with the (Cole et al., 1998) . SDS = standard deviation scores; = presence of a feature in an affected subject; Â indicates absence of a feature in an affected subject; CMAP = compound muscle action potential; RPE = retinal pigment epithelium; ffERG = full-field electroretinography.
membrane fraction as would be expected for an integral membrane protein, and exhibited their projected molecular weight of 46 kDa (Fig. 2B ).
In vivo phospholipid radiolabelling
We next determined the capacity of human EPT1 and mutant EPT1 Arg112Pro to synthesize PE in vivo. To do so, the level of radiolabelled ethanolamine incorporated into phospholipid was determined as described previously (Henneberry and McMaster, 1999) . Radiolabelled ethanolamine is incorporated into PE by the CDP-ethanolamine pathway, in yeast the PE synthesized by this pathway can be converted to phosphatidylcholine (PC) by PE methyltransferases (Kodaki and Yamashita, 1987; Henry et al., 2012) . Thus, the total radiolabel present in the PE plus PC fraction is indicative of the total activity of the ethanolaminephosphotransferase enzyme present. The amount of radiolabelled ethanolamine incorporated into phospholipid for mutant EPT1 Arg112Pro was dramatically diminished, being only 3% that of wild-type EPT1 (Fig. 2C) . Consistent with this, previous enzyme activity studies of yeast Cpt1 determined that amino acid substitutions at this residue also result in significant decrease in enzyme activity (Williams and McMaster, 1998) . Thus, there is a substantive reduction in EPT1 activity due to mutation of p.Arg112 to Pro, consistent with a loss-of-function mutation.
Lipidomic analysis of blood samples
As we were unable to directly quantify PE levels in brain of affected individuals, and as brain does not efflux PE into the blood, we investigated the amount of PE in blood using mass spectrometry as an indicator for liver EPT1 activity. While there were notable increases in certain individual PE species in patients (e.g. PE36:2, PE36:4 and PE38:5; Supplementary Fig. 2A ), there was no significant difference in levels of total PE ( Supplementary Fig. 2B ), PC, lysophosphatidylcholine (LPC) or phophatidyl serine (PS) (not shown) compared with controls. Given the variation in other individual species between patients, controls and parental carriers, we are not able to determine definitively whether changes to individual biochemical species reflect abnormal biosynthesis as a result of the EPT1 mutation, or coincidental natural variation. Thus while we are unable to assess the outcome of the EPT1 mutation in brain, these findings indicate that in blood a substantive decrease in EPT1 activity does not affect overall PE levels in blood.
Discussion
Glycerophospholipids are the primary lipid species of eukaryotic cell membranes, of which the major classes include PC and PE (Gibellini and Smith, 2010) . PE is normally the second most abundant phospholipid in eukaryotic membranes after PC, constituting 25-45% of phospholipid content (Vance and Tasseva, 2013) . PE provides vital structural support to cellular membranes, sustains the function of intrinsic membrane proteins, and is involved in anti-inflammatory, proapoptotic, autophagic, and cell surface attachment functions (Menon et al., 1993; Momchilova and Markovska, 1999; Ichimura et al., 2000; Okamoto et al., 2004; Raetz et al., 2007; Braverman and Moser, 2012; Rockenfeller et al., 2015) . PE also plays an integral role in membrane architecture via its unique biophysical properties , which were fractionated into soluble (S100) and membrane (P100) fractions, and probed using anti-DDK antibodies. Pgk1 and Dpm1 are soluble and membrane fraction loading and fractionation purification controls, respectively. EV = empty vector control. (C) Mid-log phase cells were radiolabelled with 14 C-ethanolamine for 1 h. As a positive control yeast strain HJ001 (cpt1::LEU2) transformed with an empty vector was also radiolabelled; this strain possess the wild-type genomic allele of yeast EPT1 (yEPT1). Cells were processed for lipid extraction and the radioactivity associated with PE and PC was determined.
that are essential for key cell division and membrane fusion processes (Mileykovskaya and Dowhan, 2005; Signorell et al., 2009 ). These properties are conferred by the shape of PE and its ability to form reverse non-lamellar structures. The Kennedy pathway is the main biosynthetic route for PE in most mammalian cells including the brain (Zelinski and Choy, 1982; Tijburg et al., 1989; Arthur and Page, 1991) . The final step of this Kennedy pathway transfers phosphoethanolamine from CDP-ethanolamine to a lipid anchor such as DAG, and is catalysed by two known enzymes; EPT1 and CEPT1 (Henneberry and McMaster, 1999; Henneberry et al., 2002; Wright and McMaster, 2002; Schuiki and Daum, 2009 ). Here we identify autosomal recessive p.Arg112Pro alteration of EPT1 in patients with a complex form of HSP. Our enzyme activity studies show a markedly deleterious effect of the substitution on EPT1 catalytic activity. This may be predicted to lead to altered PE fatty acyl Kennedy pathway content and/or synthesis, and the potentially significant alterations to some PE species detected in blood of patients may be consistent with this. Notably, we detected no clear alteration in overall PE content in blood. This may be explained by compensatory activity of CEPT that synthesises PE from the same biochemical source (CDP-ethanolamine), or by the synthesis of PE from PS, either of which may potentially mask changes in specific species PE levels arising due to EPT1 mutation. Thus despite the apparent normalization of total PE levels in blood, potential differences with respect to PE level in the CNS, which could not be assessed in this study, or the abnormalities that we detected in levels of specific PE species in blood, seem likely to account for the clinical features associated with EPT1 mutation. Consistent with this, there is some clinical overlap between the affected individuals described here with those of PE plasmalogen deficiency disorders such as rhizomelic chondrodysplasia punctata (RCDP), a condition characterized by skeletal abnormalities. While there are significant clinical differences between these disorders, cleft palate, spasticity and neuroimaging findings consistent with hypomyelination are features of both conditions, which may be indicative of a common outcome on developmental pathways and neuromorphogenesis due to aberrant PE biosynthesis and reduced levels of plasmalogens, substantial components of myelin.
Taken together, our findings provide new and important insight into the biological role of the Kennedy pathway in mammalian development and neurological function, and document the first human disorder arising due to Kennedy pathway dysfunction.
Web resources
